Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of $1.41, $1.13 better than the analyst estimate of $0.28. Revenue for the quarter came in at $440 million versus the consensus estimate of $259.15 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.